title: Asparagus polysaccharide and gum with hepatic artery embolization induces tumor growth and inhibits angiogenesis in an orthotopic hepatocellular carcinoma model.
abstract: Liver cancer is one of leading digestive malignancies with high morbidity and mortality. There is an urgent need for the development of novel therapies for this deadly disease. It has been proven that asparagus polysaccharide, one of the most active derivates from the traditional medicine asparagus, possesses notable antitumor properties. However, little is known about the efficacy of asparagus polysaccharide as an adjuvant for liver cancer chemotherapy. Herein, we reported that asparagus polysaccharide and its embolic agent form, asparagus gum, significantly inhibited liver tumor growth with transcatheter arterial chemoembolization (TACE) therapy in an orthotopic hepatocellular carcinoma (HCC) tumor model, while significantly inhibiting angiogenesis and promoting tumor cell apoptosis. Moreover, asparagine gelatinous possessed immunomodulatory functions and showed little toxicity to the host. These results highlight the chemotherapeutic potential of asparagus polysaccharide and warrant a future focus on development as novel chemotherapeutic agent for liver cancer TACE therapy.
authors.affiliation: Department of Radiology, Shanghai Municipal Hospital of Traditional Chinese Medicine (TCM) Affiliated to Shanghai University of TCM, Shanghai, 2Longgang Central Hospital; ENT hospital of Longgang Central Hospital; Otolaryngology Institute of Shenzhen University, Shenzhen, 3Rizhao Municipal Hospital of Traditional Chinese Medicine, Rizhao, 4Teaching and Research Section of Epidemiology, Hunan Normal University, Changsha, China E-mail : minguang_zhang2013@163.com; chan.tone@gmail.com.
authors.forename: Ling-Ling
authors.initials: LL
authors.lastname: Weng
authors.forename: Jian-Feng
authors.initials: JF
authors.lastname: Xiang
authors.forename: Jin-Bo
authors.initials: JB
authors.lastname: Lin
authors.forename: Shang-Hui
authors.initials: SH
authors.lastname: Yi
authors.forename: Li-Tao
authors.initials: LT
authors.lastname: Yang
authors.forename: Yi-Sheng
authors.initials: YS
authors.lastname: Li
authors.forename: Hao-Tao
authors.initials: HT
authors.lastname: Zeng
authors.forename: Sheng-Ming
authors.initials: SM
authors.lastname: Lin
authors.forename: Dong-Wei
authors.initials: DW
authors.lastname: Xin
authors.forename: Hai-Liang
authors.initials: HL
authors.lastname: Zhao
authors.forename: Shu-Qi
authors.initials: SQ
authors.lastname: Qiu
authors.forename: Tao
authors.initials: T
authors.lastname: Chen
authors.forename: Min-Guang
authors.initials: MG
authors.lastname: Zhang
mesh_terms: D000818:Animals; D027761:Asparagus Plant / Q000737:chemistry*; D015153:Blotting, Western; D002279:Carcinoma 256, Walker / Q000098:blood supply / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000401:mortality / Q000473:pathology* / Q000517:prevention & control*; D016461:Chemoembolization, Therapeutic; D006499:Hepatic Artery / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D008297:Male; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D011134:Polysaccharides / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D015996:Survival Rate; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
chemical_list: D011134:Polysaccharides